Heart failure & cardiomyopathiesDiagnostic or prognostic study
124 I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis
- Diagnostic accuracy study
- prospective
- multicentre (18 US centres)
- single-group
- blinded image review
- blinded adjudication
Authors' conclusion
124I-evuzamitide PET/CT is highly sensitive and specific for diagnosing cardiac amyloidosis with an acceptable safety profile.
Study context
- Population
- Adults with suspected cardiac amyloidosis presenting for diagnostic evaluation, without established cardiac or systemic amyloidosis170 included
- Participants
- 195 adults
- Outcome
- Sensitivity and specificity of 124I-evuzamitide for the diagnosis of cardiac amyloidosis (coprimary)
Performance
As reported in the abstract
Diagnosis of cardiac amyloidosis (coprimary: sensitivity and specificity)
Overall sensitivity
94% (95% CI, 85%-98%; P < .001)
Overall specificity
86% (95% CI, 77%-92%; P < .001)
Further findings
PPV and NPV for cardiac amyloidosis
- PPV
- 85% (95% CI, 75%-92%)
- NPV
- 94% (95% CI, 87%-98%)
Original publication
124 I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis. JAMA. Published 30 August 2026. doi:10.1001/jama.2026.17361
Summarised from the published abstract; every number is checked against it